SCHEMBL6541433

SCHEMBL6541433

CN(C)CCOc1cc(NS(=O)(=O)c2cc(Cl)c(Cl)s2)ccc1I

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.43
UTS2R Q9UKP6 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
CCR4 P51679 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.38
LMNA P02545 2/20 0.35
IKBKB O14920 1/20 0.35
HTT P42858 1/20 0.35
ALDH1A1 P00352 2/20 0.35
FABP4 P15090 1/20 0.35
DUT P33316 1/20 0.35
MEN1 O00255 1/20 0.34
PABPC1 P11940 1/20 0.34
KMT2A Q03164 1/20 0.34
ACLY P53396 1/20 0.34
MAPT P10636 1/20 0.34
KDR P35968 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542579 0.90 UTS2R (0.47) KITUTS2RSMN1; SMN2CCR4PTGES2
SCHEMBL6542131 0.83 CDK1 (0.51) UTS2RSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6541965 0.81 UTS2R (0.52) KITUTS2RSMN1; SMN2CCR4LMNA
SCHEMBL6541270 0.81 PSEN1 (0.44) UTS2RLMNAFABP4ACLYMAPT
SCHEMBL6541306 0.78 PFKFB3 (0.41) UTS2RSMN1; SMN2LMNAALDH1A1FABP4
SCHEMBL6542544 0.78 UTS2R (0.42) UTS2RSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6542040 0.78 CACNA1B (0.46) UTS2RSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6541457 0.78 SMN1; SMN2 (0.59) KITUTS2RSMN1; SMN2LMNAHTT
SCHEMBL6542613 0.77 UTS2R (0.52) UTS2RSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6542508 0.76 UTS2R (0.48) UTS2RSMN1; SMN2LMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US claimed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP claimed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO claimed
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP disclosed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR KIT 1424/4885UTS2R 1/4885SMN1; SMN2 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.